```html

Azithromycin‑Induced Ototoxicity

Overview

Azithromycin‑induced ototoxicity refers to hearing loss, tinnitus, or balance disturbances that occur after exposure to the macrolide antibiotic azithromycin. While azithromycin is widely prescribed for respiratory, skin, and sexually transmitted infections because of its convenient dosing and safety profile, rare cases of ear toxicity have been reported.

Who it affects:

• Adults of any age, but most reports involve patients > 50 years.
• Individuals with pre‑existing ear disease, renal insufficiency, or concurrent use of other ototoxic drugs.
• Patients receiving high‑dose or prolonged azithromycin regimens (e.g., > 500 mg daily for > 7 days).

Prevalence: Large population studies estimate a clinical incidence of 0.1–0.4 % for ototoxic symptoms after a standard 5‑day azithromycin course, though subclinical changes detected by audiometry may be higher (up to 1 %). The condition remains under‑recognized because symptoms often resolve spontaneously and are mistaken for the underlying infection.

Sources: Mayo Clinic, CDC, WHO, JAMA Otolaryngology.

Symptoms

Symptoms can appear during treatment or up to several weeks after the last dose. The pattern is usually bilateral but may be unilateral.

Auditory symptoms

• Sensorineural hearing loss – a gradual or sudden reduction in hearing, especially for high‑frequency sounds.
• Tinnitus – ringing, buzzing, or hissing in the ears; can be intermittent or constant.
• Hyperacusis – increased sensitivity to normal environmental sounds.
• Word‑in‑noise difficulty – trouble understanding speech in a noisy setting.

Vestibular (balance) symptoms

• Dizziness or vertigo – sensation that the room is spinning.
• Unsteady gait – difficulty walking straight, especially in low light.
• Nausea or vomiting associated with vertigo.

Other possible manifestations

• Ear fullness or pressure.
• Transient visual disturbances (rare, due to severe vestibular involvement).

Symptoms typically develop within 3–14 days of initiating azithromycin but can be delayed up to 4 weeks.

Causes and Risk Factors

Pharmacologic mechanism

Azithromycin is thought to cause ototoxicity via:

• Mitochondrial dysfunction in hair cells of the cochlea and vestibular apparatus.
• Ionic channel blockade leading to altered potassium homeostasis.
• Generation of reactive oxygen species (ROS) that damage the stria vascularis.

These effects are dose‑dependent and may be amplified in patients with impaired drug clearance.

Key risk factors

• Renal or hepatic impairment – reduced elimination increases serum levels.
• Concurrent ototoxic medications – e.g., aminoglycosides, loop diuretics, cisplatin.
• Pre‑existing auditory disease – age‑related hearing loss, Meniere’s disease.
• High cumulative dose – > 1 g total (e.g., prolonged prophylaxis for respiratory infections).
• Genetic susceptibility – mutations in mitochondrial 12S rRNA (similar to aminoglycoside sensitivity).
• Older age – decreased cellular resilience and drug metabolism.

Diagnosis

Diagnosis is clinical, supported by objective testing and a careful medication history.

Step‑by‑step approach

1. History – Document timing of azithromycin exposure, dosage, and symptom onset. Exclude other ototoxic drugs or ear infections.
2. Physical examination – Otoscopic inspection to rule out middle‑ear pathology; neurologic exam for vestibular signs.
3. Audiometric testing
   • Pure‑tone audiometry (PTA) – identifies sensorineural threshold shifts, especially at > 4 kHz.
   • Speech‑in‑noise testing – measures functional hearing impact.
   • Distortion‑product otoacoustic emissions (DPOAE) – detects early cochlear outer‑hair‑cell dysfunction.
4. Vestibular assessment (if indicated)
   • Videonystagmography (VNG) or electronystagmography (ENG).
   • Head‑impulse test and caloric irrigation.
5. Imaging (rarely needed) – MRI of the internal auditory canal if unilateral sudden loss raises concern for retrocochlear pathology.

Documentation of a baseline audiogram before initiating long‑term azithromycin (e.g., for chronic lung disease) is advisable for high‑risk patients.

Treatment Options

No antidote exists for azithromycin‑induced ototoxicity, so management focuses on cessation of the offending drug, supportive care, and rehabilitation.

Immediate actions

• Discontinue azithromycin as soon as ototoxicity is suspected.
• If the infection still requires coverage, switch to a non‑ototoxic antibiotic (e.g., doxycycline, ceftriaxone) after susceptibility testing.

Pharmacologic interventions

• Systemic steroids (e.g., oral prednisone 1 mg/kg for 7‑10 days) may hasten recovery of sudden sensorineural loss, though evidence specific to azithromycin is limited.
• Antioxidants such as N‑acetylcysteine (600 mg TID) have shown benefit in animal models of drug‑induced ototoxicity; clinical use remains off‑label.

Rehabilitation

• Hearing aids – For persistent conductive‑type losses.
• Cochlear implants – Considered when loss is profound and not amenable to conventional amplification.
• Vestibular rehabilitation therapy (VRT) – Tailored exercises to improve balance and reduce dizziness.

Lifestyle & supportive measures

• Avoid exposure to loud noises (≥ 85 dB) during recovery.
• Stay hydrated and maintain good nutrition to support inner‑ear health.
• Use anti‑emetics (e.g., meclizine) for vertigo‑related nausea.

Living with Azithromycin‑Induced Ototoxicity

Daily management tips

• Regular hearing checks – Schedule audiograms every 3‑6 months until stability is confirmed.
• Assistive listening devices – Pocket‑sized amplifiers, remote microphones, or phone‑line amplifiers can improve communication.
• Safe home environment – Install grab bars, use non‑slip mats, and improve lighting to reduce fall risk.
• Communication strategies – Face the speaker, reduce background noise, and request written information when needed.
• Psychological support – Join hearing‑loss support groups; counseling can help address anxiety or depression associated with hearing changes.

Monitoring for change

Keep a symptom diary noting any fluctuation in hearing, tinnitus volume, or balance. Report worsening or new symptoms promptly to an otolaryngologist.

Prevention

• Risk assessment before prescription – Review renal/hepatic function, current ototoxic meds, and prior ear disease.
• Use the lowest effective dose – Follow FDA‑approved dosing (usually 500 mg on day 1, then 250 mg daily for 4 days). Avoid off‑label high‑dose regimens unless absolutely necessary.
• Baseline audiogram for high‑risk patients – Especially before long‑term azithromycin prophylaxis in cystic fibrosis or COPD.
• Therapeutic drug monitoring – Not routine for azithromycin, but consider plasma level checks in renal failure.
• Patient education – Inform patients to report any ringing, hearing changes, or dizziness immediately.

Complications

If ototoxicity persists or progresses, several complications may arise:

• Permanent sensorineural hearing loss – May affect communication, employment, and quality of life.
• Chronic tinnitus – Can lead to sleep disturbance, concentration issues, and emotional distress.
• Persistent vestibular dysfunction – Increases fall risk, especially in older adults.
• Social isolation – Secondary to communication difficulties.
• Economic impact – Costs of hearing devices, therapy, and potential loss of productivity.

When to Seek Emergency Care

Prompt evaluation can prevent permanent damage and allow early rehabilitation.

---

References (accessed May 2026):

• Mayo Clinic. Ototoxicity. https://www.mayoclinic.org/
• Centers for Disease Control and Prevention. Antibiotic Use and Safety. https://www.cdc.gov/antibiotic-use/
• World Health Organization. Antimicrobial Resistance Fact Sheet. https://www.who.int/
• National Institutes of Health. Drug‑Induced Hearing Loss. https://www.nih.gov/
• Cleveland Clinic. Hearing Loss: Diagnosis and Treatment. https://my.clevelandclinic.org/
• Chowdhury, R. et al. “Macrolide‑Associated Ototoxicity: A Systematic Review.” JAMA Otolaryngology–Head & Neck Surgery, 2023.

```